The Fox Chase Chemical Diversity Center Announces it Has Been Awarded a Phase II SBIR Grant With the Title “A Novel Therapeutic for Invasive Candidiasis”
Doylestown, PA. June 16, 2014– FCCDC is pleased to announce that it has been awarded a Phase II SBIR grant (R44 AI106270), with the title “A Novel Therapeutic for Invasive Candidiasis” ($750,000/yr/2 yrs).